טוען...
Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial
We describe the results from a human clinical trial of a dengue virus serotype-1, purified-inactivated vaccine (DENV-1 PIV) adjuvanted with aluminum hydroxide. This first-in-man, Phase 1, open-label clinical trial consisted of two groups of flavivirus-naïve healthy adult volunteers that received two...
שמור ב:
הוצא לאור ב: | Am J Trop Med Hyg |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
The American Society of Tropical Medicine and Hygiene
2015
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4559679/ https://ncbi.nlm.nih.gov/pubmed/26149862 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4269/ajtmh.14-0819 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|